Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial

Results from the randomized phase II NIPINEC trial (GCO-001), published in the Journal of Clinical Oncology, evaluated the efficacy of nivolumab alone versus nivolumab combined with ipilimumab in patients with previously treated advanced neuroendocrine carcinoma (NEC). Neuroendocrine carcinomas are rare, aggressive malignancies with very limited treatment options after progression on first-line platinum-based chemotherapy, representing a significant area of unmet medical need. The trial provides important prospective randomized data on immune checkpoint inhibitor strategies in this difficult-to-treat population, where evidence has historically relied on small retrospective series. While the phase II design limits the immediate practice-changing potential of these findings, the data will help guide future phase III trials and inform clinical decision-making for oncologists treating advanced NEC.